

Ibex AI-Powered Pathology: Driving Clinical Excellence and Accelerated Biomarker Development

Manuela Vecsler

Select a CATEGORY: Biotech/Pharma

Select one SESSION per abstract from the list below *

“From Detection to Prediction: Diagnosing Disease Before Symptoms.”

**You may delete the section instructions, leaving only the bolded bullet title
Answers below should not exceed 60 words per question:**

- **Executive Summary / Investment Rational:**

Ibex transforms cancer diagnosis with AI. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis by developing clinical-grade AI algorithms and digital workflows that help detect and grade cancer in biopsies. Ibex also empowers biopharmaceutical partners to optimize therapeutic pipelines by providing high-fidelity, AI-driven tissue analysis and regulatory-grade evidence.

- **Core Technology:**

Ibex's platform uses AI to automatically analyze digitized biopsy slides. Trained on over 10 million slides, our algorithms detect and grade cancer alongside 100+ other morphologies. The system supports clinical labs in primary diagnosis and biomarker quantification, as well as pharma partners in identifying novel expressions, such as HER2-Ultralow, to improve diagnostic accuracy and reduce clinical trial failure risk.

- **Product Profile/Pipeline:**

We are the market leaders in AI-powered cancer diagnostics in pathology. The Ibex platform is the first and most widely deployed AI-technology in pathology and is used as part of everyday routine, supporting pathologists and providers worldwide in improving the quality and accuracy of diagnosis, for prostate, breast and gastric pathology, and biomarker scoring in breast cancer.

- **Business Strategy:**

We have deployed the Ibex platform for prostate, breast and gastric cancer worldwide and working on expanding tissue coverage /depth and global deployments, alone and in collaboration with our channel partners, such as Roche, Philips, Sectra, etc. We are also developing an AI platform for rapid biomarker development to allow prototyping of IHC biomarkers from pan-tumor and various scoring schemes.

- **What's Next?**

We are quantifying the financial impact of our technology, focusing on reimbursement and efficiency gains like rapid diagnosis and reduced spending on ancillary tests. Proven outcomes include lower misdiagnosis rates and better patient results. The Ibex platform is CE-IVDR approved, FDA 510k cleared, and holds multiple security certificates, validating its readiness for global clinical and commercial scaling.